Skip to search formSkip to main contentSkip to account menu

LCL161

Known as: Smac Mimetic LCL161 
An orally bioavailable second mitochondrial-derived activator of caspases (SMAC) mimetic and inhibitor of IAP (Inhibitor of Apoptosis Protein) family… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent Terminology

Broader (1)

Thiazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Design and synthesis of peptide-based chimeric molecules to induce degradation of the estrogen and androgen receptors.
2019
2019
Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis
Background: Outcomes in patients (pts) with relapsed/refractory (R/R) myelofibrosis (MF) post JAK inhibitor are poor [overall… 
2017
2017
Interim Phase 2 Clinical Trial Results for LCL161, an Oral Smac Mimetic, in Patients with Intermediate or High Risk Myelofibrosis
Background: For patients (pts) with intermediate or high risk myelofibrosis (MF) who have failed or are intolerant to JAK… 
2016
2016
Results for Phase II Clinical Trial of LCL161, a SMAC Mimetic, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF) or Post-Essential Thrombocytosis…
Background: There is no standard therapy for patients (pts) with intermediate (Int)-2 or high risk myelofibrosis (MF) who have… 
2015
2015
Inhibition of Bcl-2 or IAP proteins does not provoke mutations in surviving cells.
2015
2015
A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC).
1014 Background: LCL161 is a small molecule that induces apoptosis by inactivating inhibitor of apoptosis proteins (IAPs). LCL161… 
2014
2014
Targeting inhibitor of apoptosis proteins for cancer therapy: a double-edge sword?
Evasion of programmed cell death is a hallmark of human cancers. Inhibitor of apoptosis (IAP) proteins such as X-chromosome… 
Highly Cited
2012
Highly Cited
2012
Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells.
2012
2012
Abstract P6-11-06: A phase Ib study of LCL161, an oral inhibitor of apoptosis (IAP) antagonist, in combination with weekly paclitaxel in patients with advanced solid tumors
Background: Impaired apoptosis is a common feature of cancer cells and may contribute to chemoresistance. LCL161 is an oral small… 
2010
2010
Abstract 2775: A phase I study of LCL161, an oral IAP inhibitor, in patients with advanced cancer
Introduction: LCL161 is a potent small molecule mimetic of the Smac mitochondrial protein. Like Smac, it binds to inhibitor of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)